Drug Profile
Dutasteride/tadalafil - Dongkook Pharmaceutical
Alternative Names: DKF 313; Tadalafil/dutasteride - Dongkook PharmaceuticalLatest Information Update: 06 Oct 2023
Price :
$50
*
At a glance
- Originator Dongkook Pharmaceutical
- Class Antiandrogens; Antihypertensives; Antineoplastics; Aza compounds; Azasteroids; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Eye disorder therapies; Fluorinated hydrocarbons; Gastrokinetics; Heart failure therapies; Indenes; Indoles; Ischaemic heart disorder therapies; Ketones; Pyridones; Quinolines; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Benign prostatic hyperplasia
Most Recent Events
- 12 Jun 2023 Dongkook Pharmaceutical completes a phase III trial in Benign prostatic hyperplasia in South Korea (PO) (NCT04947631)
- 27 Jul 2021 Phase-III clinical trials in Benign prostatic hyperplasia in South Korea (PO) (NCT04947631)
- 01 Jul 2021 Dongkook plans a phase III trial for Benign prostatic hyperplasia in South Korea in July 2021 (NCT04947631)